Introduction: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible to undergo this treatment. The benefit of systemic treatment for these patients is limited at the cost of considerable morbidity. Hence, there is a need for appropriate palliative treatment options for patients with MPM. As MPM rarely disseminates outside the abdominal cavity, these patients might benefit from local treatment. A higher, more effective dose of chemotherapy can directly be delivered at the site of the disease. Systemic uptake will be limited, likely resulting in less toxicity. The aim of the INTERACT MESO trial is to determine the maximum tolerable dose of intraperitoneal paclitaxel monotherapy in patients with MPM. Secondary endpoints are to assess safety and toxicity, feasibility and the pharmacokinetic profile of this treatment.
Methods And Analysis: The INTERACT MESO trial is a prospective, open-label, single-centre, phase I study with a classic three-plus-three dose escalation design. The study population consists of adult patients with primary MPM, without extra-abdominal disease, who are not eligible to undergo CRS-HIPEC. According to standard of care work-up for CRS-HIPEC, patients will undergo diagnostic laparoscopy to determine the feasibility of CRS-HIPEC. In case CRS-HIPEC is not considered feasible, a peritoneal port-a-cath (PAC) system will be placed. Through this PAC, 8-16 weekly cycles of intraperitoneal chemotherapy will be administered.
Ethics And Dissemination: The Central Committee on Research Involving Human Subjects (CCMO, The Hague, The Netherlands) and the Medical Research Ethics Committee (METC, Rotterdam, The Netherlands) have granted permission to carry out this study protocol. The results of this trial will be submitted for publication in a peer-reviewed scientific journal.
Trial Registration Number: NL9718. EudraCT: 2021-003637-11.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226944 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2022-062907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy on serum stromal-derived factor-1α (SDF-1α) and chemokine ligand 5 (CXCL-5) levels in patients with ovarian cancer after tumor cell debulking surgery.
Anticancer Drugs
January 2025
Oncology gynecology, The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China.
Article Synopsis
- The study focused on the effect of combining bevacizumab with standard chemotherapy on specific serum markers in ovarian cancer patients after surgery.
- A total of 89 patients were randomly assigned to either a control group (standard chemo) or a research group (chemo + bevacizumab), with results showing improved outcomes in the research group, including higher disease remission and treatment effectiveness rates.
- After treatment, significant drops in tumor biomarkers and serum levels of SDF-1α and CXCL-5 were noted in the research group compared to the control group, suggesting the combination therapy might be more effective.
Analysis of oxytocin and oxytocin receptor expressions after hand therapy treatment in a mouse model of chemotherapy-induced peripheral neuropathy .
Neuro Endocrinol Lett
December 2024
Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo, Japan.
Objectives: We aimed to investigate the effect of hand therapy (HT) on oxytocin and oxytocin receptor expression in a chemotherapy-induced peripheral neuropathy (CIPN) model mouse.
Methods: CIPN model mouse was induced by intraperitoneal injection of paclitaxel (PTX; 4 mg/kg) on days 0, 2, 4 and 6 of the study. HT was performed on the CIPN mice once daily for 14 consecutive days, starting on day 8 after the PTX injection.
Extract and Its Active Metabolite α-Cyperone Alleviates Paclitaxel-Induced Neuropathic Pain via the Modulation of the Norepinephrine Pathway.
Metabolites
December 2024
Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02453, Republic of Korea.
Background: Paclitaxel is a widely used anticancer drug for ovarian, lung, breast, and stomach cancers; however, its clinical use is often limited by the side effects of peripheral neuropathy. This study evaluated the effects of () extract and its active metabolite, α-cyperone, on paclitaxel-induced neuropathic pain.
Methods: The oral administration of extract at doses of 500 mg/kg and intraperitoneal administration of α-cyperone at doses of 480 and 800 μg/kg prevented both the development of cold and mechanical pain.
Paclitaxel-induced peripheral neuropathy in male rats attenuated by calmangafodipir, a superoxide dismutase mimetic.
J Pharmacol Sci
January 2025
Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Article Synopsis
- Paclitaxel causes peripheral neuropathy, which limits its dosage, and there aren't currently effective preventative treatments.
- Researchers tested calmangafodipir, a superoxide dismutase mimetic, on male rats to see if it could prevent this nerve damage from paclitaxel.
- The study found that while paclitaxel led to pain sensitivity and nerve damage, calmangafodipir showed protective effects, preventing both symptoms and signs of neuropathy in the rats.
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Outcomes From a Tertiary Cancer Care Center in India.
Cureus
November 2024
Surgical Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, IND.
Background: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive form of cancer arising from the peritoneum. The prognosis for MPM has historically been poor, and treatment options are limited. This study evaluated the impact of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) as a treatment modality for MPM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!